took anoth look gsk model near end ep estim
trim year price-to-earnings multipl
estim repres discount pariti global pharma sector univers
averag believ gsk share fairli valu howev updat could
estim ep vs consensu reduct sinc last-
publish model ep also trim vs consensu
ep lower ep compound-annual-growth-rate
forecast versu previous industri averag signific
contributor lower turnov ep forecast increas advair brand competit
model alreadi assum launch gener advair mid
turnov estim flat vs consensu reduct sinc
last-publish work turnov also trim
vs consensu turnov lower
turnov compound-annual-growth-rate forecast versu previous industri
averag
oper margin estim vs consensu increas sinc
last-publish work margin also increas
vs consensu howev margin lower
forecast growth gross margin increas sg expans
 tax rate estim increas
share count forecast flat time
last week announc gener advair disku receiv fda complet
respons letter cite minor defici approv could receiv prior
standard time period follow date repli
previous check one fda respiratori kol get sens
could delay gener long would take resolv believ delay
like either due linger question data clinic data
believ pk data like lead delay sinc straightforward subject
much variabl
view present greatest challeng instanc gener candid would
undergon vitro studi three dose begin middl end
shelf life three differ flow rate l/m three differ particl size
pleas see page report import disclosur
gsk share perform tie compani abil deliv growth whilst launch
new drug deal advair pressur breo anoro gain traction
long way go blunt futur gener pressur advair sever new product
earli stage rollout soon launch need achiev success viiv hit big new
competit way oper restructur provid solid framework return
growth execut key rate gsk market perform pend greater visibl
new product success restructur benefit ep acceler
rilpivirin la flair/atla
full result gemini dolutegravir
uptak new launch trelegi close
tripl copd shingrix zoster vaccin
progress new strateg initi
advair gener delay and/or
competit
acceler penetr breo anoro
advair gener market near
term and/or competit
breo/anoro gain traction
incrus
increas competit pressur hiv
materi
meaning expect
greater expect pressur hiv
glaxosmithklin global biopharmaceut compani form merger glaxo
wellcom plc smithklin beecham plc gsk lead portfolio respiratori
vaccin product glaxo focu key area vaccin
outcom vitro analys would similar
advair advair vari lot-to-lot device-to-devic
potenti degre greater allow fda spec
consider room misstep therefor delay studi could
repeat time face steep hurdl
clinic data gener would assess two paramet first
salmeterol auc would measur insur bronchodil throughout
dose interv signific challeng howev fluticason
low dose would assess trough four week
good measur steroid includ one one month clinic studi
need repeat would take month complet
gsk one expans pipelin global pharma yet visibl
beyond hand product quit limit howev result also
bring updat new chief baron view dr
baron updat key shed addit light strength
also last week gsk announc posit top line result phase
studi evalu safeti efficaci
two-drug regimen dolutegravir lamivudin compar three-drug
regimen dolutegravir two nucleosid revers transcriptas inhibitor
tenofovir emtricitabin treatment nave infect adult
baselin viral load less copies/ml studi met
primari endpoint non-inferior base plasma rna
copies/ml week gsk note patient experienc virolog
failur either treatment arm develop treatment-emerg resist
full result present upcom scientif meet
believ virolog failur rate arm key two drug
regimen higher rate consid major neg
consult said idea nuc spare regimen use hold
appeal nuc safeti toler issu howev nuc
safe well toler much gain elimin one
combo modest improv safeti toler
would outweigh increas virolog failur
compani data cowen compani estim
totalgross opshar netepsturnov chgp sg salesr salestrdng pft sale incop pft salesjvsnet int pft b/f taxtax ratemi/pdiv incom basic cowen
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
compani data cowen compani estim
 advair lc ex fx hfa mdi busi patent expir advair hikma/west-ward receiv crl assum gener advair eu lc ex disku hfa mdi hfa patent expir advair mani marketsseretid advair combin disku inhalerflixotid flovent lc ex fx flixotid flovent share mainli use mdi formul protect hfa patent thru disku patent expir flovent eu lc ex fx flixotid flovent flovent lc ex fx ventolin eu lc ex fx ventolin lc ex fx veramyst eu lc ex fx veramyst furoat glucocorticoid receptor agonist allerg rhinitisflixonase/flonas lc ex fx flixonase/flonas eu lc ex fx flixonase/flonas clip cowen
compani data cowen compani estim
 lc ex fx anoro share trelegi close tripl could cannibalizeanoro eu lc ex fx anoro acetylcholin antagonist/laba copdbreo/relvar lc ex fx breo/relvar copd share trelegi close tripl could cannibalizebreo/relvar eu lc ex fx breo/relvar eu copd eubreo/relvar act beta agonist/steroid summit mortal trial miss endpointnucala lc ex fx nucala eu lc ex fx nucala mab sever asthma egpa market us eu japan qpprove high eos-copd nasal polyposi phase approv eu copd file asthma us/eu umec copd market us furoat glucocorticoid agonist asthma approv delta inhibitor copd acute/chron asthma phase ii chemokin receptor antagonist copd influenza phase ii human acut lung injuri phase domain antibodi acut lung injuri phase agonist asthma phase asthma phase rest world onlyoth respiratori sale even advair gener low singl digit growth advair genericwellbutrin lc ex fx wellbutrin eu lc ex fx wellbutrin cowen
compani data cowen compani estim
 lc ex fx epzicom/kivexa lamivudin patent expir gener launchedepzicom/kivexa eu lc ex fx epzicom/kivexa pressuringepzicom/kivexa- gilead truvadatrizivir lc ex fx trizivir zidovudin lamivudinetriziivir eu lc ex fx trizivir ziagen combivirageneras lexiva lc ex fx ageneras lexiva lexiva eu lc ex fx ageneras lexiva lexiva- inhibitorcombivir lc ex fx combivir gener competitioncombivir eu lc ex fx combivir gener competitioncombivir- dose combin epivir retrovirepivir lc ex fx epivir expir eu lc ex fx epivir cowen
compani data cowen compani estim
 lc ex fx tivicay share tivicay juluca triumeqtivicay eu lc ex fx tivicay eu hiv integras inhibitor combo lamivudin gilead bictegravir threatselzentri lc ex fx selzentri inhibitor approv treatment resist phase treatment nave pfizerselzentri eu lc ex fx selzentri eu lc ex fx triumeq fdctrimueq eu lc ex fx dolutegravir rilpivrin juluca approv eu underwaytriumeq fdc possibl could boost drug one pill integras inhibitor long act iv form tx prophylaxi phase file us/eu prevent file attach inhibitor phase heavili tx experienc pt file breakthrough design pat exp inhibitor patent expir pfizeroth good growth less lc ex fx relenza phase relenza eu lc ex fx relenza phase phase iizoviraxoth cowen
compani data cowen compani estim
 lc ex fx augmentin eu lc ex fx augmentin topoisomeras inhibitor bacteri infect phase malaria prophylaxi adult posit file antibioticoth hydroxylas inhibitor anemia chronic renal diseas oral phase type diabet gsk withdraw marketoth pediarix lc ex fx infanrix pediarix sni pentacel manufactur issu correctedinfanrix pediarix eu lc ex fx infanrix pediarix pediarix conjug dtp hep influenza neisseri mening synforix eu lc ex fx synflorix valent pneumonia non-typ influenza prohylaxi approv eu pursu cowen
compani data cowen compani estim
 lc ex fx hepat boost due shortfallhepat eu lc ex fx hepat havrix recombin hepat engerix rotarix lc ex fx rotarix eu lc ex fx rotarix vaccineboostrix lc ex fx boostrix eu lc ex fx boostrix immun tetanu diptheria pertussiscervarix lc ex fx cervarix longer sold marketcervarix eu lc ex fx cervarix could vaccin eu em rollout progress slowlyfluarix flulav lc ex fx fluarix flulav flulav eu lc ex fx fluarix flulav flulav inactiv split approv cowen
compani data cowen compani estim
 lc ex fx bexsero eu lc ex fx bexsero vaccin nvsmenveo lc ex fx menveo eu lc ex fx menveo phase iirabivert lc ex fx rabivert eu lc ex fx rabivert vaccin recombin varicella zoster prevent effect across entir age rang apprd us acip recmmd eu replac prophylaxi chmp posit opinion analysi underway next gen syncyti viru prophylaxi matern immun group matern immun exacerb via influenza moraxella catarrhali prophylaxi tuberculosi prophylaxi phase iiother guidanc mid-to-high singl digit vs productscoreg lc ex fx coreg eu lc ex fx coreg emhepsera japanhepsera chronic hepat gilead cowen
compani data cowen compani estim
 imitrex lc ex fx imigran imitrex launch formsimigran imitrex eu lc ex fx imigran imitrex imitrex- lc ex fx lamict lost exclus end xr repres saleslamict eu lc ex fx lamict launch litig settlement teva allow gener chewabl solid tab lc ex fx lovaza gener hold trx sharelovaza japanlovaza ethyl ester high triglycerid new competit market decliningrequip lc ex fx requip eu lc ex fx requip indic boost patent exp cmpd pd use rl exclus serev lc ex fx serev eu lc ex fx serev warn clip patent expir paxil/seroxat lc ex fx paxil/seroxat eu lc ex fx paxil/seroxat clip cowen
compani data cowen compani estim
 lc ex fx valtrex eu lc ex fx valtrex herp gener launch lc ex fx zeffix eu lc ex fx zeffix hepat compound patent expir establish multipl myeloma phase i/ii file cell receptor sarcoma mm nsclc melanoma ovarian phase ii agonist mab solid heme tumor phase i/ii agonist mab cancer phase i/ii inhibitor solid heme tumor phase i/ii prioritizedoth portfolio sold novarti key combi-d trial close changeflolan lc ex fx flolan eu lc ex fx flolan arteri hypertensionvolibri lc ex fx volibri volibri eu lc ex fx volibri arteri anti-sap mab sap deplet amyloidosi phase ii cowen
compani data cowen compani estim
 lc ex fx avodart expir gener launch avodart eu lc ex fx avodart expir good growth despit finasterid gener prostat cancer file withdrawnfraxiparin eu lc ex fx fraxiparin eufraxiparin emfraxiparin aspen group except china india pakistanarixtra lc ex fx arixtra arixtra eu lc ex fx arixtra euarixtra aspen group except china india pakistanoth lc ex fx benlysta record full sale begin eu lc ex fx benlysta ab sle sq approv vascul phase myaesthenia gravi phase ii transplant reject sclerosi phase nsaid atop dermat psoriasi phase ii file us/eu kinas inhibitor uc psoriasi ra phase ii mab ra hand oa phase ii lc ex fx bactroban eu lc ex fx bactroban cowen
compani data cowen compani estim
 lc ex eu lc ex fx soriatan lc ex fx dermov dermov eu lc ex fx dermov lc ex fx duac competitionduac eu lc ex fx duac gel approv japan march dermatolog busi acquisit close sale rx sale over-the-counter guidanc low singl digit ex vaccin vs nv consum jv approx revenu annual close ribena divest ye sale sold repres ireland nv lamisil toe nail fungu fenistil skin irrit consum guidanc low mid singl digit vs guidanc low singl digit growthtarget margin guidanc low-to-mid singl digit vs cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ continu success exist portfolio notabl advair success
pipelin product especi respiratori oncolog hiv success deal
patent litig patent expir pressur particularli involv advair
